Literature DB >> 28225669

MR Enterography Assessment of Bowel Inflammation Severity in Crohn Disease Using the MR Index of Activity Score: Modifying Roles of DWI and Effects of Contrast Phases.

Jin Sil Kim1, Hye Young Jang2, Seong Ho Park1, Kyung-Jo Kim3, Kyunghwa Han4, Suk-Kyun Yang3, Byong Duk Ye3, Sang Hyoung Park3, Jong Seok Lee1, Hyun Jin Kim1.   

Abstract

OBJECTIVE: The purpose of this article is to appraise the use of the MR index of activity (MaRIA) score in evaluating Crohn disease (CD) on present-day MR enterography images, with an emphasis on determining the modifying roles of DWI and the effects of different contrast enhancement phases. SUBJECTS AND METHODS: Fifty patients prospectively underwent MR enterography, including DWI and enteric and portal phase scans, and ileocolonoscopy with segmental CD endoscopic index of severity (CDEIS) scoring within a week. Thirty-nine terminal ilea and 40 right-sided colons (mean [± SD] segmental CDEIS score, 14.3 ± 12.1) from 42 patients with CD (mean age, 27 ± 6.2 years) were finally analyzed by three independent readers. Original and modified (ulcer replaced with DWI grade) MaRIA scores were compared regarding their correlation with segmental CDEIS score, accuracy in diagnosing active (segmental CDEIS score ≥ 3) and severe (segmental CDEIS score ≥ 12) inflammation, and interobserver reproducibility. The primary analysis used portal phase data, and the agreement between portal and enteric phase scores was analyzed.
RESULTS: MaRIA and modified MaRIA scores correlated similarly with CDEIS scores (r = 0.737 and 0.742; p = 0.387) and did not significantly differ in terms of AUC values for the diagnosis of active (0.909 and 0.903; p = 0.571) or severe (0.907 and 0.892; p = 0.443) inflammation. The intraclass correlation coefficient was significantly higher for modified MaRIA than for MaRIA (0.845 and 0.701; p < 0.001). The mean difference between portal and enteric phase scores (i.e., portal minus enteric) was 0.33-0.36 score points for individual readers, and the Bland-Altman repeatability coefficient was 0.9-1.42 score points.
CONCLUSION: Interobserver reproducibility in evaluating the severity of bowel inflammation in CD using the MaRIA score can be improved by modification with DWI. MaRIA scoring provides steady results across enteric and portal phases.

Entities:  

Keywords:  Crohn disease; MR enterography; diffusion; score; severity

Mesh:

Substances:

Year:  2017        PMID: 28225669     DOI: 10.2214/AJR.16.17324

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  11 in total

1.  Imaging of the small intestine in Crohn's disease: Joint position statement of the Indian Society of Gastroenterology and Indian Radiological and Imaging Association.

Authors:  Saurabh Kedia; Raju Sharma; Govind K Makharia; Vineet Ahuja; Devendra Desai; Devasenathipathy Kandasamy; Anu Eapen; Karthik Ganesan; Uday C Ghoshal; Naveen Kalra; D Karthikeyan; Kumble Seetharama Madhusudhan; Mathew Philip; Amarender Singh Puri; Sunil Puri; Saroj K Sinha; Rupa Banerjee; Shobna Bhatia; Naresh Bhat; Sunil Dadhich; G K Dhali; B D Goswami; S K Issar; V Jayanthi; S P Misra; Sandeep Nijhawan; Pankaj Puri; Avik Sarkar; S P Singh; Anshu Srivastava; Philip Abraham; B S Ramakrishna
Journal:  Indian J Gastroenterol       Date:  2018-01-06

Review 2.  [Radiological imaging of acute infectious and non-infectious enterocolitis].

Authors:  J Wessling
Journal:  Radiologe       Date:  2018-04       Impact factor: 0.635

3.  Apparent diffusion coefficient for assessing Crohn's disease activity: a meta-analysis.

Authors:  Maximilian Thormann; Bohdan Melekh; Caroline Bär; Maciej Pech; Jazan Omari; Andreas Wienke; Hans-Jonas Meyer; Alexey Surov
Journal:  Eur Radiol       Date:  2022-09-28       Impact factor: 7.034

4.  Poor Concordance Between Clinical Activity and Endoscopic Severity in Pediatric Crohn's Disease: Before and After Induction Therapy.

Authors:  Yu Yu; Hong Zhao; Youyou Luo; Jingan Lou; Jie Chen; Youhong Fang
Journal:  Dig Dis Sci       Date:  2021-04-05       Impact factor: 3.199

5.  Selection and Reporting of Statistical Methods to Assess Reliability of a Diagnostic Test: Conformity to Recommended Methods in a Peer-Reviewed Journal.

Authors:  Ji Eun Park; Kyunghwa Han; Yu Sub Sung; Mi Sun Chung; Hyun Jung Koo; Hee Mang Yoon; Young Jun Choi; Seung Soo Lee; Kyung Won Kim; Youngbin Shin; Suah An; Hyo-Min Cho; Seong Ho Park
Journal:  Korean J Radiol       Date:  2017-09-21       Impact factor: 3.500

Review 6.  A review of magnetic resonance enterography-based indices for quantification of Crohn's disease inflammation.

Authors:  Noa Rozendorn; Marianne Michal Amitai; Rami Abraham Eliakim; Uri Kopylov; Eyal Klang
Journal:  Therap Adv Gastroenterol       Date:  2018-04-13       Impact factor: 4.409

7.  Magnetic resonance imaging and Crohn's disease endoscopic index of severity: Correlations and concordance.

Authors:  Nai-Yi Zhu; Xue-Song Zhao; Fei Miao
Journal:  World J Gastroenterol       Date:  2018-06-07       Impact factor: 5.742

8.  Magnetic resonance enterography (MRE) and ultrasonography (US) in the study of the small bowel in Crohn's disease: state of the art and review of the literature.

Authors:  Rosa Manetta; Ilaria Capretti; Noemi Belleggia; Claudia Marsecano; Angelo Viscido; Federico Bruno; Francesco Arrigoni; Liheng Ma; Giuseppe Guglielmi; Alessandra Splendiani; Ernesto Di Cesare; Carlo Masciocchi; Antonio Barile
Journal:  Acta Biomed       Date:  2019-04-24

9.  Lemann Index for Assessment of Crohn's Disease: Correlation with the Quality of Life, Endoscopic Disease Activity, Magnetic Resonance Index of Activity and C- Reactive Protein.

Authors:  Vestina Straksyte; Gediminas Kiudelis; Irina Gineikiene; Dainius Janciauskas; Algidas Basevicius; Saulius Lukosevicius; Limas Kupcinskas
Journal:  Open Med (Wars)       Date:  2019-11-07

Review 10.  Small bowel imaging in Crohn's disease patients.

Authors:  James Gauci; Lara Sammut; Martina Sciberras; Naomi Piscopo; Kristian Micallef; Kelvin Cortis; Pierre Ellul
Journal:  Ann Gastroenterol       Date:  2018-05-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.